Ultrasonography of the Adrenal Gland

With appropriate techniques and using liver, spleen or kidney as an acoustic window, normal adrenal gland and adrenal lesions can be delineated by ultrasonography. The right adrenal gland is usually evaluated by transverse oblique scans and coronal scans, respectively, through the anterior and middle axillary line, while the left adrenal gland is investigated by an oblique coronal scan mainly through the posterior axillary line. For adrenal lesions, ultrasonography has a sensitivity of 74–97%, a specificity of 61–96%, and an accuracy of 70–97%. The diagnostic accuracy depends on the scanning technique and expertise of the operator, the body status of the patient, the size and functional status of the lesion, and the ultrasonographic quality. Small adrenal nodules, ileus, obesity, fatty liver, and large body status account for most of the reasons for decreased accuracy. Small adrenal nodules less than 3 cm in diameter mainly comprise functioning cortical adenomas, nonfunctioning cortical adenomas, nodular hyperplasia, and metastases. Most small adrenal masses are homogeneous and hypoechoic, and the echo patterns are nonspecific. Large adrenal masses greater than 3 cm in diameter mainly include primary adrenocortical carcinoma, lymphoma, metastasis, lymphoma, and pheochromocytoma. The echogenicity of a large adrenal mass may be hyperechoic and heterogeneous because of the higher incidence of necrosis and hemorrhage. Other uncommon adrenal masses are myelolipoma, hematoma, granulomatous lesions, hemangioma, and adrenal cysts of various origins. The differential diagnoses of a hyperechoic adrenal mass include neuroblastoma, myelolipoma, and tumor with central necrosis or heterogeneity. Calcification is encountered in both benign and malignant processes. It is sometimes difficult to differentiate benign adrenal masses from malignant lesions. Dynamic computed tomography, magnetic resonance imaging, and positron emission tomography play critical complementary roles in such an instance

Construct Validity and Reliability of the SARA Gait and Posture Sub-scale in Early Onset Ataxia

Aim: In children, gait and posture assessment provides a crucial marker for the early characterization, surveillance and treatment evaluation of early onset ataxia (EOA). For reliable data entry of studies targeting at gait and posture improvement, uniform quantitative biomarkers are necessary. Until now, the pediatric test construct of gait and posture scores of the Scale for Assessment and Rating of Ataxia sub-scale (SARA) is still unclear. In the present study, we aimed to validate the construct validity and reliability of the pediatric (SARA(GAIT/POSTURE)) sub-scale.Methods: We included 28 EOA patients [15.5 (6-34) years; median (range)]. For inter-observer reliability, we determined the ICC on EOA SARA(GAIT/POSTURE) subscores by three independent pediatric neurologists. For convergent validity, we associated SARA(GAIT/POSTURE) sub-scores with: (1) Ataxic gait Severity Measurement by Klockgether (ASMK; dynamic balance), (2) Pediatric Balance Scale (PBS; static balance), (3) Gross Motor Function Classification Scale-extended and revised version (GMFCSE&amp; R), (4) SARA-kinetic scores (SARA(KINETIC); kinetic function of the upper and lower limbs), (5) Archimedes Spiral (AS; kinetic function of the upper limbs), and (6) total SARA scores (SARA(TOTAL); i.e., summed SARA(GAIT/POSTURE), SARA(KINETIC), and SARA(SPEECH) sub-scores). For discriminant validity, we investigated whether EOA co-morbidity factors (myopathy and myoclonus) could influence SARA(GAIT/POSTURE) sub-scores.Results: The inter-observer agreement (ICC) on EOA SARA(GAIT/POSTURE) sub-scores was high (0.97). SARA(GAIT/POSTURE) was strongly correlated with the other ataxia and functional scales [ASMK (r(s) = -0.819; p &lt;0.001); PBS (r(s) = -0.943; p &lt;0.001); GMFCS-E&amp; R (rs = -0.862; p &lt;0.001); SARA(KINETIC) (r(s) = 0.726; p &lt;0.001); AS (r(s) = 0.609; p = 0.002); and SARATOTAL (rs = 0.935; p &lt;0.001)]. Comorbid myopathy influenced SARA(GAIT/POSTURE) scores by concurrent muscle weakness, whereas comorbid myoclonus predominantly influenced SARA(KINETIC) scores.Conclusion: In young EOA patients, separate SARA(GAIT/POSTURE) parameters reveal a good inter-observer agreement and convergent validity, implicating the reliability of the scale. In perspective of incomplete discriminant validity, it is advisable to interpret SARA(GAIT/POSTURE) scores for comorbid muscle weakness.</p

Determinants of SARS-CoV-2 receptor gene expression in upper and lower airways

The recent outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has led to a worldwide pandemic. One week after initial symptoms develop, a subset of patients progresses to severe disease, with high mortality and limited treatment options. To design novel interventions aimed at preventing spread of the virus and reducing progression to severe disease, detailed knowledge of the cell types and regulating factors driving cellular entry is urgently needed. Here we assess the expression patterns in genes required for COVID-19 entry into cells and replication, and their regulation by genetic, epigenetic and environmental factors, throughout the respiratory tract using samples collected from the upper (nasal) and lower airways (bronchi). Matched samples from the upper and lower airways show a clear increased expression of these genes in the nose compared to the bronchi and parenchyma. Cellular deconvolution indicates a clear association of these genes with the proportion of secretory epithelial cells. Smoking status was found to increase the majority of COVID-19 related genes including ACE2 and TMPRSS2 but only in the lower airways, which was associated with a significant increase in the predicted proportion of goblet cells in bronchial samples of current smokers. Both acute and second hand smoke were found to increase ACE2 expression in the bronchus. Inhaled corticosteroids decrease ACE2 expression in the lower airways. No significant effect of genetics on ACE2 expression was observed, but a strong association of DNA- methylation with ACE2 and TMPRSS2- mRNA expression was identified in the bronchus.</p

Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals

We conduct a genome-wide association study (GWAS) of educational attainment (EA) in a sample of ~3 million individuals and identify 3,952 approximately uncorrelated genome-wide-significant single-nucleotide polymorphisms (SNPs). A genome-wide polygenic predictor, or polygenic index (PGI), explains 12-16% of EA variance and contributes to risk prediction for ten diseases. Direct effects (i.e., controlling for parental PGIs) explain roughly half the PGI's magnitude of association with EA and other phenotypes. The correlation between mate-pair PGIs is far too large to be consistent with phenotypic assortment alone, implying additional assortment on PGI-associated factors. In an additional GWAS of dominance deviations from the additive model, we identify no genome-wide-significant SNPs, and a separate X-chromosome additive GWAS identifies 57

Genome-wide association study identifies 74 loci associated with educational attainment

Educational attainment is strongly influenced by social and other environmental factors, but genetic factors are estimated to account for at least 20% of the variation across individuals1. Here we report the results of a genome-wide association study (GWAS) for educational attainment that extends our earlier discovery sample1,2 of 101,069 individuals to 293,723 individuals, and a replication study in an independent sample of 111,349 individuals from the UK Biobank. We identify 74 genome-wide significant loci associated with the number of years of schooling completed. Single-nucleotide polymorphisms associated with educational attainment are disproportionately found in genomic regions regulating gene expression in the fetal brain. Candidate genes are preferentially expressed in neural tissue, especially during the prenatal period, and enriched for biological pathways involved in neural development. Our findings demonstrate that, even for a behavioural phenotype that is mostly environmentally determined, a well-powered GWAS identifies replicable associated genetic variants that suggest biologically relevant pathways. Because educational attainment is measured in large numbers of individuals, it will continue to be useful as a proxy phenotype in efforts to characterize the genetic influences of related phenotypes, including cognition and neuropsychiatric diseases

Construct Validity and Reliability of the SARA Gait and Posture Sub-scale in Early Onset Ataxia

Aim: In children, gait and posture assessment provides a crucial marker for the early characterization, surveillance and treatment evaluation of early onset ataxia (EOA). For reliable data entry of studies targeting at gait and posture improvement, uniform quantitative biomarkers are necessary. Until now, the pediatric test construct of gait and posture scores of the Scale for Assessment and Rating of Ataxia sub-scale (SARA) is still unclear. In the present study, we aimed to validate the construct validity and reliability of the pediatric (SARA(GAIT/POSTURE)) sub-scale.Methods: We included 28 EOA patients [15.5 (6-34) years; median (range)]. For inter-observer reliability, we determined the ICC on EOA SARA(GAIT/POSTURE) subscores by three independent pediatric neurologists. For convergent validity, we associated SARA(GAIT/POSTURE) sub-scores with: (1) Ataxic gait Severity Measurement by Klockgether (ASMK; dynamic balance), (2) Pediatric Balance Scale (PBS; static balance), (3) Gross Motor Function Classification Scale-extended and revised version (GMFCSE&amp; R), (4) SARA-kinetic scores (SARA(KINETIC); kinetic function of the upper and lower limbs), (5) Archimedes Spiral (AS; kinetic function of the upper limbs), and (6) total SARA scores (SARA(TOTAL); i.e., summed SARA(GAIT/POSTURE), SARA(KINETIC), and SARA(SPEECH) sub-scores). For discriminant validity, we investigated whether EOA co-morbidity factors (myopathy and myoclonus) could influence SARA(GAIT/POSTURE) sub-scores.Results: The inter-observer agreement (ICC) on EOA SARA(GAIT/POSTURE) sub-scores was high (0.97). SARA(GAIT/POSTURE) was strongly correlated with the other ataxia and functional scales [ASMK (r(s) = -0.819; p &lt;0.001); PBS (r(s) = -0.943; p &lt;0.001); GMFCS-E&amp; R (rs = -0.862; p &lt;0.001); SARA(KINETIC) (r(s) = 0.726; p &lt;0.001); AS (r(s) = 0.609; p = 0.002); and SARATOTAL (rs = 0.935; p &lt;0.001)]. Comorbid myopathy influenced SARA(GAIT/POSTURE) scores by concurrent muscle weakness, whereas comorbid myoclonus predominantly influenced SARA(KINETIC) scores.Conclusion: In young EOA patients, separate SARA(GAIT/POSTURE) parameters reveal a good inter-observer agreement and convergent validity, implicating the reliability of the scale. In perspective of incomplete discriminant validity, it is advisable to interpret SARA(GAIT/POSTURE) scores for comorbid muscle weakness.</p

Construct validity and reliability of the SARA gait and posture sub-scale in early onset ataxia

Aim: In children, gait and posture assessment provides a crucial marker for the early characterization, surveillance and treatment evaluation of early onset ataxia (EOA). For reliable data entry of studies targeting at gait and posture improvement, uniform quantitative biomarkers are necessary. Until now, the pediatric test construct of gait and posture scores of the Scale for Assessment and Rating of Ataxia sub-scale (SARA) is still unclear. In the present study, we aimed to validate the construct validity and reliability of the pediatric (SARAGAIT/POSTURE) sub-scale. Methods: We included 28 EOA patients [15.5 (6-34) years; median (range)]. For inter-observer reliability, we determined the ICC on EOA SARAGAIT/POSTURE subscores by three independent pediatric neurologists. For convergent validity, we associated SARAGAIT/POSTURE sub-scores with: (1) Ataxic gait Severity Measurement by Klockgether (ASMK; dynamic balance), (2) Pediatric Balance Scale (PBS; static balance), (3) Gross Motor Function Classification Scale -extended and revised version (GMFCSE & R), (4) SARA-kinetic scores (SARAKINETIC; kinetic function of the upper and lower limbs), (5) Archimedes Spiral (AS; kinetic function of the upper limbs), and (6) total SARA scores (SARATOTAL; i.e., summed SARAGAIT/POSTURE, SARAKINETIC, and SARASPEECH sub-scores). For discriminant validity, we investigated whether EOA co-morbidity factors (myopathy and myoclonus) could influence SARAGAIT=POSTURE sub-scores. Results: The inter-observer agreement (ICC) on EOA SARAGAIT/POSTURE sub-scores was high (0.97). SARAGAIT/POSTURE was strongly correlated with the other ataxia and functional scales [ASMK (rs = -0.819; p < 0.001); PBS (rs = -0.943; p < 0.001); GMFCS-E & R (rs = -0.862; p < 0.001); SARAKINETIC (rs = 0.726; p < 0.001); AS (rs = 0.609; p = 0.002); and SARATOTAL (rs = 0.935; p < 0.001)]. Comorbid myopathy influenced SARAGAIT/POSTURE scores by concurrent muscle weakness, whereas comorbid myoclonus predominantly influenced SARAKINETIC scores. Conclusion: In young EOA patients, separate SARAGAIT/POSTURE parameters reveal a good inter-observer agreement and convergent validity, implicating the reliability of the scale. In perspective of incomplete discriminant validity, it is advisable to interpret SARAGAIT/POSTURE scores for comorbid muscle weakness

VISUAL ASSESSMENT OF SEGMENTAL MUSCLE ULTRASOUND IMAGES IN SPINA BIFIDA APERTA

In spina bifida aperta (SBA), spinal MRI provides a surrogate marker to estimate muscle damage caudal to the myelomeningocele (MMC). This muscle damage by the MMC can be quantified by intra-individual comparison of muscle ultrasound density (MUD) caudal versus cranial to the MMC (dMUD 5 [MUDcaudal-to-the-MMC] - [MUDcranial-to-the-MMC]). Quantitative dMUD assessment requires time, equipment and expertise, whereas it could also be visually determined by differences in muscle echodensity caudal vs. cranial to the MMC (visual-dMUD). If visual and quantitative dMUD correspond, visual dMUD assessment could provide a clinical screening parameter. In 100 SBA muscle ultrasound recordings of patients with various MMC levels, we aimed to compare quantitative dMUD (dMUD = [MUDcalf-muscle/S1] - [MUDquadriceps-muscle/L2-L4]) with visual dMUD assessments by 20 different observers. Results indicate that quantitative dMUD can be visually detected (sensitivity 86%; specificity 57%), implicating that visual dMUD screening could provide a quick, clinical screening tool for muscle impairment by the MMC. (E-mail: [email protected]) (C) 2012 World Federation for Ultrasound in Medicine & Biology

Visual screening of muscle ultrasound images in children

In children, non-invasive muscle ultrasound (MU) imaging has become increasingly important for the detection of neuromuscular pathology, by either quantitative or visual assessment. MU quantification requires time, expertise and equipment. If application of visual MU screening provides reliable results, ubiquitous application could be advocated. Previously, we found that visual MU screening can reliably detect segmental neuromuscular alterations within a patient. Analogously, we reasoned that visual MU screening could discern pathologic MU images from healthy controls. We therefore investigated visual screening results by 20 clinical observers (involving 100 MU images, with [n = 53] and without [n = 47] neuromuscular pathology). MU screening revealed adequate sensitivity, specificity and negative predictive value (85%, 75% and 82%, respectively). MU-experienced observers revealed higher specificity than MU-inexperienced observers (86% vs. 69%, p = 0.005). We conclude that clinical observers can identify neuromuscular pathology by visual screening. To enhance specificity, a secondary view by an expert appears advisory